281 related articles for article (PubMed ID: 19539217)
1. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.
Copelan EA; Crilley PA; Szer J; Dodds AJ; Stevenson D; Phillips G; Elder P; Nivison-Smith I; Avalos BR; Penza S; Topolsky D; Sobecks R; Kalaycio M; Bolwell BJ
Biol Blood Marrow Transplant; 2009 Jul; 15(7):851-5. PubMed ID: 19539217
[TBL] [Abstract][Full Text] [Related]
2. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
3. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
[TBL] [Abstract][Full Text] [Related]
4. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
5. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
6. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases].
He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
8. Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Reiter E; Greinix HT; Brugger S; Keil F; Rabitsch W; Mannhalter C; Schwarzinger I; Höcker P; Fischer G; Dieckmann K; Hinterberger W; Linkesch W; Schneider B; Lechner K; Kalhs P
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S86-8. PubMed ID: 9916646
[TBL] [Abstract][Full Text] [Related]
9. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
[TBL] [Abstract][Full Text] [Related]
12. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
[TBL] [Abstract][Full Text] [Related]
13. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
Thall PF; Champlin RE; Andersson BS
Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
[TBL] [Abstract][Full Text] [Related]
17. Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
Takami A; Chuhjo T; Nakao S
Haematologica; 2002 Jun; 87(6):659-61. PubMed ID: 12031925
[No Abstract] [Full Text] [Related]
18. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
Weisser M; Schleuning M; Ledderose G; Rolf B; Schnittger S; Schoch C; Schwerdtfeger R; Kolb HJ
Bone Marrow Transplant; 2004 Dec; 34(12):1083-8. PubMed ID: 15489879
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score).
Bacigalupo A; Gualandi F; Van Lint MT; Sessarego M; Frassoni F; Occhini D; Lamparelli T; Oneto R; Vitale V; Corvo R
Bone Marrow Transplant; 1993 Nov; 12(5):443-8. PubMed ID: 8298554
[TBL] [Abstract][Full Text] [Related]
20. Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.
J Clin Oncol; 1999 Jun; 17(6):1858-68. PubMed ID: 10561226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]